Vaccine Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Device (Syringes and Jet Injectors), By Route Of Administration (Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 7.92 Billion
CAGR (2026-2031)	7.13%
Fastest Growing Segment	Syringes
Largest Market	North America
Market Size (2031)	USD 11.97 Billion

Market Overview

The Global Vaccine Delivery Devices Market will grow from USD 7.92 Billion in 2025 to USD 11.97 Billion by 2031 at a 7.13% CAGR. Vaccine delivery devices are specialized medical apparatuses designed to administer immunobiological agents into the body, primarily consisting of syringes, needles, jet injectors, and microneedle patches. The market is fundamentally supported by the escalating global prevalence of infectious diseases and the rigorous expansion of government-led immunization initiatives aimed at achieving universal coverage. This substantial demand for administration tools is evidenced by the massive procurement volumes required for international health programs; according to UNICEF, in 2024, the organization delivered 886.19 million syringes to support vaccination efforts globally. These figures underscore the critical reliance on scalable delivery systems to meet public health mandates.

However, a significant challenge impeding market expansion is the management of hazardous medical waste generated by single-use devices. The disposal of used needles and syringes poses severe environmental and safety risks, necessitating complex waste management infrastructure that is often resource-intensive and lacking in developing regions. Consequently, the logistical and financial burden associated with ensuring safe disposal and preventing needle-stick injuries remains a critical barrier to the seamless distribution and adoption of conventional vaccine delivery mechanisms in emerging markets.

Key Market Drivers

Technological advancements in microneedle and needle-free injection systems are fundamentally reshaping the Global Vaccine Delivery Devices Market by addressing logistical challenges and improving patient compliance. These innovations, particularly high-density microarray patches, eliminate the need for cold-chain storage and professional administration, making them ideal for distribution in low-resource settings. This shift toward minimally invasive solutions is attracting significant capital to accelerate commercialization and manufacturing scale-up. According to BioSpace, August 2025, in the 'Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology' article, Vaxxas secured approximately AUD 90 million to advance its proprietary patch technology toward market readiness. Such substantial investment underscores the industry's commitment to transitioning from traditional needle-and-syringe methods to more scalable, user-friendly alternatives that enhance immunological efficiency.

Concurrently, the expansion of global immunization programs and government funding acts as a primary catalyst for market volume, driving the procurement of delivery devices to meet universal health targets. International bodies and national governments are intensifying efforts to reach zero-dose children and combat preventable diseases through robust vaccination campaigns. According to the World Health Organization, July 2025, in the 'Immunization coverage' report, global coverage for the first dose of the human papillomavirus (HPV) vaccine rose to 31% in 2024, reflecting a concerted push to widen preventative care access. To support these large-scale initiatives, manufacturers are rapidly expanding their industrial footprint. According to BD, January 2025, in the 'BD Boosts U.S. Manufacturing of Critical Medical Devices' press release, the company increased its domestic production capacity for safety-engineered injection devices by more than 40% to sustain the growing needs of the healthcare system.

Download Free Sample Report

Key Market Challenges

The effective management of hazardous medical waste generated by single-use delivery systems constitutes a formidable barrier impeding the expansion of the Global Vaccine Delivery Devices Market. As immunization initiatives scale to reach universal coverage, the concurrent surge in used syringes and needles creates a substantial logistical and financial bottleneck, particularly in emerging economies where disposal infrastructure is insufficient. This deficiency forces healthcare systems to divert critical capital towards waste treatment and containment solutions rather than the procurement of additional delivery units, thereby decelerating market adoption rates and complicating supply chain dynamics.

Furthermore, the operational risks associated with this accumulation of hazardous material directly restrict the seamless distribution of conventional vaccine tools. According to the World Health Organization, in late 2024, approximately 16 billion injections were administered globally, yet a significant proportion of the resulting sharps waste remained unaccounted for in safe disposal streams. This massive volume of bio-hazardous material creates severe regulatory and safety liabilities that deter market penetration in resource-constrained regions. Consequently, the inability to cost-effectively manage the lifecycle of these devices acts as a critical constraint, limiting the overall growth potential of the market.

Key Market Trends

The Expansion of Intranasal and Mucosal Vaccine Delivery Systems is emerging as a critical trend, driven by the need to establish robust immunity at the primary site of viral entry. Unlike traditional injectables that primarily induce systemic protection, these novel mucosal platforms elicit local immune responses, such as IgA production in the respiratory and gastrointestinal tracts, which are essential for blocking transmission. This shift is further accelerated by the development of oral formats that eliminate needle-phobia and simplify administration logistics. Validating the efficacy of these systems, according to Vaxart, Inc., September 2025, in the 'Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate' press release, the company’s second-generation oral vaccine constructs produced statistically significant increases in blocking antibodies of 141% and 94% against specific norovirus strains, highlighting the potency of mucosal delivery.

Concurrently, the Proliferation of Prefilled Syringes with Advanced Safety Features is reshaping the manufacturing landscape to prioritize scalability and rapid deployment. This trend is characterized by the adoption of Blow-Fill-Seal (BFS) technology, which integrates the formation, filling, and sealing of the device into a continuous process, thereby reducing contamination risks and supply chain complexity compared to glass-based alternatives. This transition supports high-volume production required for global health mandates while ensuring dosage accuracy. Exemplifying this industrial scale-up, according to ApiJect Systems, Corp., May 2025, in the 'Amneal and ApiJect to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.' press release, a new strategic collaboration was established to install manufacturing lines with the capacity to produce approximately 250 to 300 million units annually, underscoring the massive industrial commitment to next-generation prefilled solutions.

Segmental Insights

The Syringes segment represents the fastest-growing category within the Global Vaccine Delivery Devices Market, driven by a significant industry shift toward pre-filled and safety-engineered systems. This rapid expansion is primarily fueled by the heightened demand for dosage accuracy and reduced vaccine wastage during mass immunization campaigns. Furthermore, global health institutions such as the World Health Organization strongly advocate for the mandatory use of auto-disable mechanisms to prevent needle-stick injuries and prohibit device reuse. These critical safety and efficiency requirements are accelerating the adoption of advanced syringe technologies over traditional delivery methods.

Regional Insights

North America leads the Global Vaccine Delivery Devices Market, driven by a well-established healthcare system and the widespread adoption of modern immunization technologies. The region benefits from substantial government funding for public health programs and the presence of major medical device manufacturers that support the development of safety-engineered syringes and needle-free systems. Additionally, the U.S. Food and Drug Administration provides a clear regulatory framework that facilitates the timely approval of new delivery methods. High public awareness regarding infectious diseases and favorable reimbursement policies further reinforce the region's strong market position.

Recent Developments

• In January 2025, Kindeva Drug Delivery announced an exclusive partnership with Emervax to co-develop a breakthrough vaccine delivery solution. This collaboration integrates Kindeva’s solid-coated microneedle array patch technology with Emervax’s proprietary circular RNA vaccine platform. The partnership aims to produce a thermostable, needle-free alternative for administering vaccines against emerging viruses such as Yellow Fever and Ebola. By leveraging this patch-based system, the companies intend to enhance vaccine stability and minimize cold chain dependencies. They expect the joint technology to enter clinical trials by 2026, offering a more accessible option for global immunization efforts.
• In January 2025, Micron Biomedical received a $3.7 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of its needle-free vaccine delivery system. The funding supports research into the company's dissolvable microarray-based technology, which is designed to simplify the administration of rapid-response vaccines during disease outbreaks. This innovative "button-like" applicator applies vaccines directly to the skin, potentially removing the need for complex cold-chain storage and trained medical personnel. The project builds on previous clinical successes and aims to establish a scalable, patient-friendly solution for global pandemic preparedness and routine immunization.
• In June 2024, PharmaJet revealed that its Tropis Intradermal Needle-free System was chosen for a major house-to-house polio immunization campaign in Somalia. Working alongside international health agencies, the company supplied over 250,000 needle-free syringes to support the effort to eradicate type-2 poliovirus. The campaign focused on vaccinating children using this device, which eliminates the risks associated with sharps waste and needle reuse. This deployment highlighted the capability of jet injection technology to facilitate rapid and safe vaccine administration in challenging field environments, ensuring high coverage rates without the logistical burden of traditional needles.
• In March 2024, Schott Pharma announced a strategic investment of $371 million to construct a new manufacturing facility in Wilson, North Carolina. This state-of-the-art plant will focus on producing prefillable polymer syringes specifically designed to meet the rigorous requirements for deep-cold storage and transport of mRNA vaccines and medications. As the company’s first U.S. site dedicated to these advanced delivery systems, the project aims to triple Schott Pharma's supply of glass and polymer syringes to the American market by 2030. This expansion serves to strengthen the domestic supply chain for essential biologic therapies and immunization programs.

Key Market Players

• Becton Dickinson & Company
• Bioject Medical Technologies, Inc.
• PharmaJet, Inc.
• Vaxxas, Inc.
• Gerresheimer AG
• SCHOTT AG
• Corium, LLC
• 3M Company
• Croda International Plc
• Meiji Holdings Co., Ltd.

By Device	By Route Of Administration	By Region
Syringes and Jet Injectors	Intradermal Vaccination Intramuscular Vaccination Subcutaneous Vaccination	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Vaccine Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Vaccine Delivery Devices Market, By Device:

• Syringes and Jet Injectors

• Vaccine Delivery Devices Market, By Route Of Administration:

• Intradermal Vaccination
• Intramuscular Vaccination
• Subcutaneous Vaccination

• Vaccine Delivery Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE